|
|
|
|
|
|
| A Pragmatic Approach To Developing A Rare Disease Drug | White Paper | Curia | We are beginning to see a rise in the interest of developing “orphan drugs." Discover challenges and considerations associated with the expedited development and how to successfully work through them. |
|
|
| Manual CQV Vs. AI-Powered CQV | Infographic | ValGenesis | Still validating the manual way? With AI-powered CQV, you can reclaim hours lost to protocols and audit prep. What used to take weeks is now done in minutes. |
|
|
|
|
By Katie Anderson, Chief Editor, Pharmaceutical Online | After nearly 20 years in the pharmaceutical industry, Samir Shah, director of regulatory CMC for medical products and combination products at AstraZeneca, knows how beneficial charisma can be for the pharmaceutical professional. That’s why he presented the topic at the 2025 RAPS Convergence. | |
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Connect With Pharmaceutical Online: |
|
|
|